湖南斯奇生物制药

Hunan Siqi Biopharmaceutical, a subsidiary of the publicly traded Jiuzhitang Co., Ltd., is a Chinese pharmaceutical company specializing in the development and production of biological immunomodulators. The company is best known for its flagship product, Siqi (BCG Polysaccharide and Nucleic Acid Injection), which is widely utilized in China for the treatment of allergic and respiratory conditions such as bronchial asthma and allergic rhinitis. Founded in 1993 and headquartered in Changsha, the company operates modern GMP-certified manufacturing facilities dedicated to biological extracts and vaccine-related research. Siqi Biopharmaceutical plays a significant role in the immunology segment of its parent company, focusing on leveraging biological components to regulate immune responses. The company continues to maintain a strong market presence in the respiratory and dermatological therapeutic areas within the Chinese healthcare sector.